IRLAB Therapeutics 推进美多培坦神经系统治疗的 III 期试验。 IRLAB Therapeutics advances towards Phase III trial for mesdopetam neurological treatment.

IRLAB Therapeutics 宣布其美多培坦 III 期临床试验的准备工作取得重大进展，美多培坦是一种旨在解决神经系统疾病的治疗方法。 IRLAB Therapeutics has announced significant advancements in its preparations for the Phase III clinical trial of mesdopetam, a treatment aimed at addressing neurological conditions. 报告强调该公司致力于推进这种治疗,这可能会对病人护理产生影响。 The report highlights the company's commitment to progressing this therapy, which could potentially impact patient care. 没有提供关于审判设计和预期时间表的进一步细节。 Further details on the trial design and expected timelines were not provided.